HUP0402061A2 - Rosszindulatú daganatok kezelésére alkalmas, egy biszfoszfonát, egy COX-2 inhibitor és egy taxol kombinációját tartalmazó gyógyszerkészítmények - Google Patents

Rosszindulatú daganatok kezelésére alkalmas, egy biszfoszfonát, egy COX-2 inhibitor és egy taxol kombinációját tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0402061A2
HUP0402061A2 HU0402061A HUP0402061A HUP0402061A2 HU P0402061 A2 HUP0402061 A2 HU P0402061A2 HU 0402061 A HU0402061 A HU 0402061A HU P0402061 A HUP0402061 A HU P0402061A HU P0402061 A2 HUP0402061 A2 HU P0402061A2
Authority
HU
Hungary
Prior art keywords
taxol
cox
inhibitor
treatment
combination
Prior art date
Application number
HU0402061A
Other languages
English (en)
Inventor
Jonathan Green
Allan Lipton
Lois Mary Witters
Original Assignee
Novartis Ag
Allan Lipton
Lois Mary Witters
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Allan Lipton, Lois Mary Witters filed Critical Novartis Ag
Publication of HUP0402061A2 publication Critical patent/HUP0402061A2/hu
Publication of HUP0402061A3 publication Critical patent/HUP0402061A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány olyan, rosszindulatú betegségek, különösen acsontmetasztázisok kialakulásával vagy az excesszív csontreszorpcióvalegyütt járó rosszindulatú betegségek kezelésére alkalmasgyógyszerkészítményekre vonatkozik, amelyek egy egyidejű, egymás utánivagy szeparált felhasználásra alkalmas kombinációban egybiszfoszfonátot, egy COX-2 inhibitort és/vagy taxolt vagy egytaxolszármazékot tartalmaznak. A találmány tárgyát képezi továbbá egyeljárás egy rosszindulatú betegségben szenvedő beteg kezelésére,amelynek során a betegnek egy biszfoszfonát hatásos mennyiségét, ésegy COX-2 inhibitor hatásos mennyiségét és/vagy taxol vagy egy taxol-származék hatásos mennyiségét adják be. Ó
HU0402061A 2001-10-19 2002-10-18 Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, cox-2 inhibitor and a taxol HUP0402061A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34592101P 2001-10-19 2001-10-19
PCT/EP2002/011696 WO2003035081A1 (en) 2001-10-19 2002-10-18 Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol

Publications (2)

Publication Number Publication Date
HUP0402061A2 true HUP0402061A2 (hu) 2005-02-28
HUP0402061A3 HUP0402061A3 (en) 2007-05-29

Family

ID=23357099

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402061A HUP0402061A3 (en) 2001-10-19 2002-10-18 Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, cox-2 inhibitor and a taxol

Country Status (26)

Country Link
US (1) US7345088B2 (hu)
EP (1) EP1443942B1 (hu)
JP (1) JP2005506371A (hu)
KR (1) KR20040066103A (hu)
CN (1) CN100372539C (hu)
AT (1) ATE382347T1 (hu)
AU (1) AU2002363089B2 (hu)
BR (1) BR0213410A (hu)
CA (1) CA2461085A1 (hu)
CO (1) CO5570672A2 (hu)
DE (1) DE60224429T2 (hu)
DK (1) DK1443942T3 (hu)
EC (1) ECSP045054A (hu)
ES (1) ES2301710T3 (hu)
HK (1) HK1080733A1 (hu)
HU (1) HUP0402061A3 (hu)
IL (2) IL161090A0 (hu)
MX (1) MXPA04003671A (hu)
NO (1) NO20042056L (hu)
NZ (1) NZ532282A (hu)
PL (1) PL367707A1 (hu)
PT (1) PT1443942E (hu)
RU (1) RU2317819C2 (hu)
SI (1) SI1443942T1 (hu)
WO (1) WO2003035081A1 (hu)
ZA (1) ZA200402089B (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0204756D0 (en) * 2002-02-28 2002-04-17 Novartis Ag Organic compounds
GB0328040D0 (en) * 2003-12-03 2004-01-07 Coleman Robert E Pharmaceutical uses of bisphosphonates
FR2939314A1 (fr) * 2008-12-04 2010-06-11 Univ Victor Segalen Bordeaux 2 Nouvelles compositions et methodes pour la potentialisation des signaux d'apoptose dans les cellules tumorales
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
ES2650665T3 (es) * 2009-07-31 2018-01-19 Grünenthal GmbH Método de cristalización y biodisponibilidad
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1187130A (zh) * 1995-06-06 1998-07-08 麦克公司 用二磷酸盐预防与免疫抑制疗法有关的骨损失
CZ20012320A3 (cs) * 1998-12-23 2002-10-16 G. D. Searle & Co. Léčivo s obsahem inhibitoru cyklooxygenázy-2 a jednoho nebo více antineoplastických činidel pro kombinační terapii při léčení neoplasie
AU3653301A (en) * 2000-01-28 2001-08-07 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug

Also Published As

Publication number Publication date
BR0213410A (pt) 2004-11-03
RU2004115337A (ru) 2005-04-20
HUP0402061A3 (en) 2007-05-29
DE60224429D1 (de) 2008-02-14
EP1443942A1 (en) 2004-08-11
IL161090A (en) 2010-04-15
KR20040066103A (ko) 2004-07-23
HK1080733A1 (en) 2006-05-04
NO20042056L (no) 2004-05-18
PL367707A1 (en) 2005-03-07
WO2003035081A1 (en) 2003-05-01
CN1703226A (zh) 2005-11-30
IL161090A0 (en) 2004-08-31
DE60224429T2 (de) 2008-12-18
ZA200402089B (en) 2005-06-22
RU2317819C2 (ru) 2008-02-27
EP1443942B1 (en) 2008-01-02
DK1443942T3 (da) 2008-05-19
US7345088B2 (en) 2008-03-18
US20050014726A1 (en) 2005-01-20
CN100372539C (zh) 2008-03-05
JP2005506371A (ja) 2005-03-03
CO5570672A2 (es) 2005-10-31
MXPA04003671A (es) 2005-06-20
CA2461085A1 (en) 2003-05-01
AU2002363089B2 (en) 2006-02-16
ATE382347T1 (de) 2008-01-15
ES2301710T3 (es) 2008-07-01
ECSP045054A (es) 2004-05-28
NZ532282A (en) 2006-02-24
SI1443942T1 (sl) 2008-08-31
PT1443942E (pt) 2008-04-07

Similar Documents

Publication Publication Date Title
BR0209365A (pt) Usos farmacêuticos de bisfosfonatos
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
NO20063373L (no) CD40-antistoff-formuleringer og fremgangsmater
ATE349446T1 (de) Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
UA86344C2 (ru) Способ лечения сосудистых заболеваний
HUP0402506A2 (hu) FBPáz inhibitorok és inzulinérzékenység-fokozók kombinációja diabétesz kezelésére
HUP0401903A2 (hu) Az ET-743 továbbfejlesztett alkalmazása daganatok kezelésére
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
DE60027209D1 (de) Arzneimittel enthaltend hydroxyapatite zur behandlung von knochengewebserkrankungen
DE60332363D1 (de) Oligonucleotide zur behandlung von prostatakrebs und anderen krebserkrankungen
DE60309887D1 (de) Kombination von einem aromatasehemmer mit einem bisphosphonat
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
GB0020504D0 (en) Therapeutic method
ATE251911T1 (de) Löslische hla-g enthaltende zusammensetsungen zur behandlung entzündlichen hautkrankheiten
MY134059A (en) Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
ATE376425T1 (de) Verfahren zur behandlung bestimmter augenkrankheiten
HUP0103557A2 (hu) Antraciklinszármazék alkalmazása májtumor kezelésére
BR0308105A (pt) Composição farmacêutica compreendendo um bisfosfonato e um inibidor de cox-2 para o tratamento de doenças de ossos
BR0315376A (pt) Combinações de benzotiadiazóis e inibidores de cox-2 para o tratamento de dor
ATE321551T1 (de) Methoden zur behandlung des kryptorchysmus
DE60003921D1 (de) Diphenyl-1,2,3-thiadiazol-3-oxide, zusammensetzungen und verfahren zur anwendung
ATE338560T1 (de) Pharmazeutische zusammentsetzung zur medizinischen behandlung von gutartiger prostathyperplasie, dessen vorbereitungsmethode und dessen therapeutische verwendung
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees